Reducing the Excess Activin Signaling Rescues Muscle Degeneration in Myotonic Dystrophy Type 2 Drosophila Model
Open Access
- 2 March 2022
- journal article
- research article
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 12 (3) , 385
Abstract
Expanded non-coding RNA repeats of CCUG are the underlying genetic causes for myotonic dystrophy type 2 (DM2). There is an urgent need for effective medications and potential drug targets that may alleviate the progression of the disease. In this study, 3140 small-molecule drugs from FDA-approved libraries were screened through lethality and locomotion phenotypes using a DM2 Drosophila model expressing 720 CCTG repeats in the muscle. We identified ten effective drugs that improved survival and locomotor activity of DM2 flies, including four that share the same predicted targets in the TGF-β pathway. The pathway comprises two major branches, the Activin and BMP pathways, which play critical and complex roles in skeletal development, maintenance of homeostasis, and regeneration. The Drosophila model recapitulates pathological features of muscle degeneration in DM2, displaying shortened lifespan, a decline in climbing ability, and progressive muscle degeneration. Increased levels of p-smad3 in response to activin signaling were observed in DM2 flies. Decreased levels of activin signaling using additional specific inhibitors or genetic method ameliorated climbing defects, crushed thoraxes, structure, and organization of muscle fibers. Our results demonstrate that a decrease in activin signaling is sufficient to rescue muscle degeneration and is, therefore, a potential therapeutic target for DM2.Keywords
Funding Information
- National Natural Science Foundation of China (81571253, 81771385, 82071273, 82101958)
- Hunan Science and Technology major project of Birth Defect cooperative control (2019SK1010)
- Natural Science Foundation of Hunan Province (2016JJ3135)
- Changsha Municipal Natural Science Foundation (kq2007073)
This publication has 48 references indexed in Scilit:
- Chemical screen reveals small molecules suppressing fragile X premutation rCGG repeat-mediated neurodegeneration in DrosophilaHuman Molecular Genetics, 2012
- RNA Foci, CUGBP1, and ZNF9 Are the Primary Targets of the Mutant CUG and CCUG Repeats Expanded in Myotonic Dystrophies Type 1 and Type 2The American Journal of Pathology, 2011
- Transforming growth factor (TGF)-β signaling in cardiac remodelingJournal of Molecular and Cellular Cardiology, 2011
- SMAD signaling drives heart and muscle dysfunction in a Drosophila model of muscular dystrophyHuman Molecular Genetics, 2010
- Mutant (CCTG)n Expansion Causes Abnormal Expression of Zinc Finger Protein 9 (ZNF9) in Myotonic Dystrophy Type 2The American Journal of Pathology, 2010
- CUGBP1 overexpression in mouse skeletal muscle reproduces features of myotonic dystrophy type 1Human Molecular Genetics, 2010
- PKC inhibition ameliorates the cardiac phenotype in a mouse model of myotonic dystrophy type 1Journal of Clinical Investigation, 2009
- Mechanisms of Muscle Degeneration, Regeneration, and Repair in the Muscular DystrophiesAnnual Review of Physiology, 2009
- A postnatal switch of CELF and MBNL proteins reprograms alternative splicing in the developing heartProceedings of the National Academy of Sciences, 2008
- Angiotensin II type 1 receptor blockade attenuates TGF-β–induced failure of muscle regeneration in multiple myopathic statesNature Medicine, 2007